The basic knowledge reported in the present study provides a strategy that treatment with FSTL1 could be a promising pharmacological intervention for attenuating MI in T2DM and function and identifies USP10-notch1 signaling pathway as a novel factor that could contribute to the prevention of MI in T2DM. This evidence concerns the gene USP10 and type 2 diabetes mellitus.